

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Status: RECRUITING

Eligibility Criteria

Age: 18 years and over

This study is NOT accepting healthy

Healthy Volunteers: volunteers

Inclusion Criteria:

- * Have a diagnosis of multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria
- * Be newly diagnosed and not considered a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT) due to: ineligible due to advanced age OR; ineligible due to the presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT OR; deferral of high-dose chemotherapy with ASCT as initial treatment
- * Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
- * A participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment
- * A participant must agree not to plan to father a child while enrolled in this study or within 100 days after the last dose of study treatment

Exclusion Criteria:

- * Received any prior therapy for multiple myeloma or smoldering myeloma other than a short course of corticosteroids (not to exceed total of 160 milligrams \[mg\] dexamethasone or equivalent). In addition, received a cumulative dose of systemic corticosteroids equivalent to greater than or equals to (\geq) 20 mg of dexamethasone within 14 days before randomization
- * Had plasmapheresis within 28 days of randomization
- * Had a stroke, transient ischemic attack, or seizure within 6 months prior to randomization
- * Known allergies, hypersensitivity, or intolerance to teclistamab or talquetamab excipients
- * Known contraindications to the use of daratumumab or lenalidomide per local prescribing information
- * Myeloma Frailty Index of ≥ 2 with the exception of participants who have a score of 2 based on age alone

Conditions & Interventions

Interventions:

DRUG: Teclistamab, DRUG: Daratumumab, DRUG: Lenalidomide, DRUG: Dexamethasone, DRUG: Talquetamab

Conditions:

Multiple Myeloma

More Information

Contact(s): Study Contact - Participate-In-This-Study1@its.jnj.com

Principal Investigator:

IRB

Number:

System ID: NCT05552222

Thank you for choosing StudyFinder. Please visit <http://studyfinder.cctr.vcu.edu> to find a Study which is right for you and contact ctrrecruit@vcu.edu if you have questions or need assistance.